公开(公告)号：US07293373B2

公开(公告)日：2007-11-13

申请号：US11286643

申请日：2005-11-23

申请人： Greg Reagan ,  Christopher Doyle ,  Florian Lang ,  Maurizio Molin

发明人： Greg Reagan ,  Christopher Doyle ,  Florian Lang ,  Maurizio Molin

IPC分类号： A43B5/04 ,  A43C11/00

CPC分类号： A43C1/003 ,  A43B3/0031 ,  A43B11/00 ,  A43C1/06 ,  A43C3/00 ,  A43C7/00 ,  A43C11/008 ,  A43C11/14

摘要： A boot incorporating techniques for making the process of tightening and loosening the laces of a boot more convenient for the wearer is disclosed. The boot may be provided with at least two independent lacing zones, the tensions of which are separately adjustable by the wearer. The zones may be secured by pulling on two laces, each of which tightens one of the two independent lacing zones. This arrangement allows the wearer to simultaneously tighten each zone, providing the wearer with the “feel” as though he or she is tightening a conventional single lacing zone boot. The laces may be simultaneously, yet independently secured by a lace lock at the upper and/or forward region of the boot. Slack may be created to facilitate loosening of the boot and easy removal of a foot from the boot by unhooking the lace from the lace guide without a corresponding distance of lace traveling through the lace lock. A release strap, graspable by the wearer, facilitates unhooking the lace.

摘要翻译： 本发明公开了一种引导装置，其特征在于，包括用于使穿戴者更方便的紧固松动过程的技术。 靴子可以设置有至少两个独立的系带区域，其张力可由穿着者单独调节。 这些区域可以通过拉两个鞋带来固定，每个鞋带收紧两个独立鞋带区中的一个。 这种布置允许佩戴者同时收紧每个区域，为佩戴者提供“感觉”，好像他或她正在收紧常规的单一系带区域靴子。 鞋带可以同时地，但是通过在靴子的上部和/或前部区域处的花边锁独立地固定。 可以创建松弛以促进靴子的松动，并且通过从蕾丝引导件脱钩蕾丝而没有鞋带穿过花边锁的相应距离，从而容易地从靴子移除脚。 由佩戴者掌握的释放带有助于脱钩蕾丝。

公开(公告)号：US20070191325A1

公开(公告)日：2007-08-16

申请号：US10591909

申请日：2005-02-10

申请人： Florian Lang

发明人： Florian Lang

IPC分类号： A61K31/573

CPC分类号： A61K31/15 ,  A61K31/16 ,  A61K31/519

摘要： Modulation of the activity of glucocorticoid inducible kinase SGK1 in pancreatic islet cells restores insulin release. Also disclosed are methods and compounds useful for the treatment of glucocorticoid induced diabetes mellitus type-2.

摘要翻译： 胰岛细胞中糖皮质激素诱导型激酶SGK1的活性调节恢复胰岛素释放。 还公开了可用于治疗糖皮质激素诱导的2型糖尿病的方法和化合物。

公开(公告)号：US20070060646A1

公开(公告)日：2007-03-15

申请号：US10574781

申请日：2004-09-16

申请人： Rolf Gericke ,  Norbert Beier ,  Oliver Poeschke ,  Lars Burgdorf ,  Helga Drosdat ,  Florian Lang

发明人： Rolf Gericke ,  Norbert Beier ,  Oliver Poeschke ,  Lars Burgdorf ,  Helga Drosdat ,  Florian Lang

IPC分类号： A61K31/277 ,  A61K31/22 ,  A61K31/165

CPC分类号： C07C251/86

摘要： The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of fibroses and inflammatory processes. In said formula: R1 and R5 independently of one another represent H, OH, OA, OAc or methyl; R2, R3, R4, R6, R7, R8, R9 and R10 independently of one another represent H, OH, OA, OAc, OCF3, Hal, NO2, CF3, A, CN, OSO2CH3, SO2CH3, NH2, or COOH; R11 represents H or CH3; A represents an alkyl comprising 1, 2, 3, or 4 C atoms; X represents CH2, CH2CH2, OCH2 or —CH(OH)— and Hal represents F, Cl, Br or I.

摘要翻译： 本发明涉及式（I）的酰腙衍生物，其为SGK抑制剂，可用于治疗与SGK相关的疾病和病症，如糖尿病，肥胖，代谢综合征（血脂异常），系统性和肺性高血压，心血管疾病 和肾脏疾病，一般用于所有类型的纤维和炎症过程。 在所述式中：R 1和R 5彼此独立地表示H，OH，OA，OAc或甲基; R 2，R 3，R 4，R 6，R 7， R 9，R 9和R 10彼此独立地表示H，OH，OA，OAc，OCF 3， >，Hal，NO 2，CF 3，A，CN，OSO 2，CH 3，SO， > 2个CH 3，NH 2或COOH; R 11表示H或CH 3; A表示包含1,2,3或4个C原子的烷基; X表示CH 2 CH 2，CH 2 CH 2，OCH 2或-CH（OH） - ，Hal表示 F，Cl，Br或I.

公开(公告)号：US20070059695A1

公开(公告)日：2007-03-15

申请号：US10547746

申请日：2003-03-05

申请人： Florian Lang

发明人： Florian Lang

IPC分类号： C12Q1/68 ,  G01N33/567

CPC分类号： C12Q1/485

摘要： The invention relates to the utilization of a substance for diagnostic determination of sgk1 (serum and glucocorticoid dependent kinase 1) and to the utilization of an active agent in order to influence sgk1 for therapeutic treatment of diseases associated with disordered activity of the tissue factor and to a diagnostic kit related thereto.

摘要翻译： 本发明涉及用于sgk1（血清和糖皮质激素依赖性激酶1）的诊断测定的物质的利用和活性剂的利用，以影响sgk1用于治疗与组织因子的无序活性相关的疾病的治疗，以及 与之相关的诊断试剂盒。

公开(公告)号：US20060240459A1

公开(公告)日：2006-10-26

申请号：US11398208

申请日：2006-04-04

申请人： Florian Lang ,  Siegfried Waldegger ,  Philipp Lang ,  Angelika Lampert ,  Hannsjoerg Seybert ,  Nikola Jeck

发明人： Florian Lang ,  Siegfried Waldegger ,  Philipp Lang ,  Angelika Lampert ,  Hannsjoerg Seybert ,  Nikola Jeck

IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C12N9/12 ,  A61K48/00

CPC分类号： C12Q1/6883 ,  C12Q2600/156

摘要： The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.

摘要翻译： 本发明涉及一种用于诊断人类或其易感性的高血压，/或过敏和/或脱发，和/或感染的可能性的方法; 涉及编码人类ClCKb蛋白质的核酸分子，其包含与野生型相比在氨基酸位置481处的遗传改变，以及其对应的片段; 涉及在严格条件下与前述核酸分子结合的核酸分子，以及与该核酸分子结合的核酸分子; 涉及由上述核酸分子编码的（多）肽; 涉及一种用于鉴定与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽调节活性的物质的方法; 涉及调节与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽的活性的物质; 制备用于治疗高血压和/或过敏和/或脱发的药物组合物和/或感染责任的方法; 至药物组合物; 以及治疗受高血压，/或过敏和/或脱发影响的人的方法和/或感染责任。

公开(公告)号：US07074573B2

公开(公告)日：2006-07-11

申请号：US10687523

申请日：2003-10-15

申请人： Florian Lang ,  Siegfried Waldegger ,  Phillipp Lang ,  Angelika Lampert ,  Hannsjoerg Seybert ,  Nikola Jeck

发明人： Florian Lang ,  Siegfried Waldegger ,  Phillipp Lang ,  Angelika Lampert ,  Hannsjoerg Seybert ,  Nikola Jeck

IPC分类号： G01N33/53 ,  C07K14/00

CPC分类号： C12Q1/6883 ,  C12Q2600/156

摘要： The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.

摘要翻译： 本发明涉及一种用于诊断人类或其易感性的高血压，/或过敏和/或脱发，和/或感染责任的方法; 涉及编码人类ClCKb蛋白质的核酸分子，其包含与野生型相比在氨基酸位置481处的遗传改变，以及其对应的片段; 涉及在严格条件下与前述核酸分子结合的核酸分子，以及与该核酸分子结合的核酸分子; 涉及由上述核酸分子编码的（多）肽; 涉及一种用于鉴定与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽调节活性的物质的方法; 涉及调节与野生型相比在氨基酸位置481遗传改变的来自ClCKb蛋白的肽的活性的物质; 制备用于治疗高血压和/或过敏和/或脱发的药物组合物和/或感染责任的方法; 至药物组合物; 以及治疗受高血压，/或过敏和/或脱发影响的人的方法和/或感染责任。

公开(公告)号：US20060121465A1

公开(公告)日：2006-06-08

申请号：US10516745

申请日：2003-06-04

申请人： Florian Lang ,  Karl Lang ,  Michael Dieter

发明人： Florian Lang ,  Karl Lang ,  Michael Dieter

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： C12Q1/485 ,  A01K2217/05 ,  G01N2333/96466

摘要： The invention relates to the use of a substance for the diagnostic detection of Sgk, especially Sgk1 and/or Sgk3, and/or PKB and/or Nedd, especially Nedd4-2, and to the use of active ingredients which influence glucose transport for treating diseases associated with disturbed glucose transport, and for fattening animals. The invention also relates to a diagnosis kit and a pharmaceutical composition comprising an active quantity of at least one active ingredient which influences glucose transport. The invention further relates to a method for producing transgenic animals.

摘要翻译： 本发明涉及用于诊断Sgk，特别是Sgk1和/或Sgk3，和/或PKB和/或Nedd，特别是Nedd4-2的诊断性检测的物质的用途，以及影响葡萄糖转运治疗的活性成分的用途 与葡萄糖转运紊乱相关的疾病，以及育肥动物。 本发明还涉及诊断试剂盒和药物组合物，其包含活性量的至少一种影响葡萄糖转运的活性成分。 本发明还涉及生产转基因动物的方法。

公开(公告)号：US20060070261A1

公开(公告)日：2006-04-06

申请号：US11286956

申请日：2005-11-23

申请人： Greg Reagan ,  Christopher Doyle ,  Florian Lang ,  Maurizio Molin

发明人： Greg Reagan ,  Christopher Doyle ,  Florian Lang ,  Maurizio Molin

IPC分类号： A43B5/04 ,  A43B5/16

CPC分类号： A43C1/003 ,  A43B3/0031 ,  A43B11/00 ,  A43C1/06 ,  A43C3/00 ,  A43C7/00 ,  A43C11/008 ,  A43C11/14

摘要： A boot incorporating techniques for making the process of tightening and loosening the laces of a boot more convenient for the wearer is disclosed. The boot may be provided with at least two independent lacing zones, the tensions of which are separately adjustable by the wearer. The zones may be secured by pulling on two laces, each of which tightens one of the two independent lacing zones. This arrangement allows the wearer to simultaneously tighten each zone, providing the wearer with the “feel” as though he or she is tightening a conventional single lacing zone boot. The laces may be simultaneously, yet independently secured by a lace lock at the upper and/or forward region of the boot. Slack may be created to facilitate loosening of the boot and easy removal of a foot from the boot by unhooking the lace from the lace guide without a corresponding distance of lace traveling through the lace lock. A release strap, graspable by the wearer, facilitates unhooking the lace.

摘要翻译： 本发明公开了一种引导装置，其特征在于，包括用于使穿戴者更方便的紧固松动过程的技术。 靴子可以设置有至少两个独立的系带区域，其张力可由穿着者单独调节。 这些区域可以通过拉两个鞋带来固定，每个鞋带收紧两个独立鞋带区中的一个。 这种布置允许佩戴者同时收紧每个区域，为佩戴者提供“感觉”，好像他或她正在收紧常规的单一系带区域靴子。 鞋带可以同时地，但是通过在靴子的上部和/或前部区域处的花边锁独立地固定。 可以创建松弛以促进靴子的松动，并且通过从蕾丝引导件脱钩蕾丝而没有鞋带穿过花边锁的相应距离，从而容易地从靴子移除脚。 由佩戴者掌握的释放带有助于脱钩蕾丝。

公开(公告)号：US20050181402A1

公开(公告)日：2005-08-18

申请号：US11044570

申请日：2005-01-28

申请人： Florian Lang ,  Siegfried Waldegger

发明人： Florian Lang ,  Siegfried Waldegger

IPC分类号： G01N33/573 ,  A61K31/70 ,  A61K38/00 ,  A61K39/395 ,  A61P13/02 ,  A61P15/00 ,  C07K14/705 ,  C12N9/12 ,  C12N15/02 ,  C12N15/54 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/577 ,  C07H21/04 ,  C07K16/40 ,  G01N33/53 ,  G01N33/567

CPC分类号： C12N9/1205 ,  A61K38/00

摘要： The present invention relates to the cloning and characterization of a human serine/threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and/or in “macromolecular crowding” in the body, such as, for example, hypernatremia, hyponatremia, diabetes. mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

摘要翻译： 本发明涉及人丝氨酸/苏氨酸激酶（h-sgk：血清和糖皮质激素依赖性激酶）的克隆和表征。 本发明还涉及用于诊断与细胞体积变化和/或体内“大分子拥挤”相关的病症的试剂，例如高钠血症，低钠血症，糖尿病。 肾功能衰竭，高分泌症，肝性脑病，炎症和微生物或病毒感染。 本发明还涉及包含h-sgk，编码h-sgk的核酸或特异性结合h-sgk的受体，特别是抗体的药物。

公开(公告)号：US5693672A

公开(公告)日：1997-12-02

申请号：US451309

申请日：1995-05-26

申请人： Andreas Weichert ,  Hans-Jochen Lang ,  Wolfgang Scholz ,  Udo Albus ,  Florian Lang

发明人： Andreas Weichert ,  Hans-Jochen Lang ,  Wolfgang Scholz ,  Udo Albus ,  Florian Lang

IPC分类号： A61K31/155 ,  A61K31/18 ,  A61K31/33 ,  A61K31/435 ,  A61K31/44 ,  A61P1/16 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P9/02 ,  A61P9/06 ,  A61P9/10 ,  A61P11/00 ,  A61P15/04 ,  A61P43/00 ,  C07C277/08 ,  C07C279/22 ,  C07C311/37 ,  C07C315/04 ,  C07C317/32 ,  C07C317/44 ,  C07C323/60 ,  C07D213/56

CPC分类号： C07C317/44 ,  C07D213/56 ,  C07C2101/02 ,  C07C2101/08 ,  C07C2101/14 ,  Y10S514/821

摘要： 3,4,5-Substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicament containing them Benzoylguanidines of the formula I ##STR1## where R(1) is R(4)--SO.sub.m or R(5)R(6)N--SO.sub.2 --, where R(4) and R(5) are alk(en)yl, --C.sub.n H.sub.2n --R(7), and where R(7) is cycloalkyl or phenyl, where R(5) is also H, R(6) is H or C.sub.1 --C.sub.4 --alkyl, R(2) is hydrogen, (cyclo)-alk(en)(yn)yl, aryl and hetaryl, R(3) is defined as R(2) and their pharmaceutically tolerable salts are described.

摘要翻译： 3,4,5-取代的苯甲酰胍，其制备方法，它们用作药物或诊断剂和含有它们的药物。其中R（1）为R（4）-SO m或R 1的式I的苯甲酰胍 （5）R（6）N-SO2-，其中R（4）和R（5）是烷（烯）基，-CnH2n-R（7），其中R（7）是环烷基或苯基，其中R （5）也是H，R（6）是H或C 1 -C 4 - 烷基，R（2）是氢，（环）-alk（en）（yn），芳基和杂芳基，R（3） 描述了R（2）及其药学上可耐受的盐。